Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Wilms Tumor 7Rhabdoid Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6Neuroblastoma 6Medulloblastoma 6Lymphoma, Non-Hodgkin 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Glioma 6Ependymoma 6Sarcoma 5Rhabdomyosarcoma 5Osteosarcoma 5Central Nervous System Neoplasms 5Sarcoma, Ewing 3Pancreatic Neoplasms 2Xanthogranuloma, Juvenile 1Thyroid Cancer, Papillary 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Nasopharyngeal Carcinoma 1Lymphoma, B-Cell 1Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Histiocytic Sarcoma 1Hematopoietic and Lymphatic System Neoplasm 1Familial ependymoma 1Duodenal Neoplasms 1Desmoid Tumors 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Phantoms, Imaging × Clear all
NCT02849496 2026-05-22

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
81 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡